Target intelligence / Profile preview

Macrophage pyroptosis pathway

Molecular classification
Other (cellular signaling pathway, not a single protein or gene)
01

Overview

The macrophage pyroptosis pathway refers to the cascade of molecular events leading to pro-inflammatory cell death (pyroptosis) in macrophages, typically triggered by recognition of pathogen-associated (PAMPs) or damage-associated (DAMPs) molecular patterns. The process involves activation of pattern recognition receptors (notably NLRP3, NLRC4, AIM2), formation of the inflammasome complex, activation of caspase-1 (canonical) or caspase-4/5/11 (non-canonical), cleavage of gasdermin D (GSDMD), and formation of membrane pores, resulting in cell lysis and release of inflammatory cytokines like IL-1β and IL-18. Pyroptosis plays a critical role in host defense, yet excessive or dysregulated macrophage pyroptosis contributes to inflammatory and infectious diseases, as well as tissue damage in conditions such as acute lung injury and sepsis[5][4][1][3][6]. Note: This entry is *not* for a single molecular target, but for a complex multi-step cell signaling pathway involving multiple proteins (such as NLRP3, caspase-1, GSDMD, etc.)[5][4][1][3][6]. The most appropriate use is as a descriptor for the pathway; if a single target is needed, refer to constituents such as "NLRP3", "Caspase-1", or "Gasdermin D".

Other names
Pyroptotic pathway in macrophagesMacrophage inflammasome-dependent cell death pathway
02

Mechanism of action

Inhibition of inflammasome assembly; Inhibition of caspase-1 or caspase-4/5/11; Inhibition/blockade of gasdermin D cleavage; Blockade of IL-1β/IL-18 signaling

03

Biological functions

Cell deathImmune responseInflammation
04

Disease associations

InflammationInfectionCancerAcute lung injury/ARDSOther inflammatory diseases
05

Safety considerations

Excessive inhibition could suppress host defense against infectionOff-target inhibition of related cell death or inflammatory processesGeneral risk of immunomodulation
06

Interacting drugs

No drugs directly target the "macrophage pyroptosis pathway" as a unit, but inhibitors/modulators of pathway components (e.g., NLRP3 inhibitors, caspase inhibitors) are studied. Examples: MCC950 (NLRP3 inhibitor), VX-765 (caspase-1 inhibitor)
07

Biomarkers

Cleaved gasdermin D (GSDMD-N)Caspase-1 (cleaved/activated)IL-1β (mature/secreted)IL-18 (mature/secreted)Lactate dehydrogenase (LDH) release (marker of lytic cell death)

Beyond the preview

Go deeper on Macrophage pyroptosis pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macrophage pyroptosis pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call